BioTelemetry (NASDAQ:BEAT) released its quarterly earnings data on Tuesday. The medical research company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09, Bloomberg Earnings reports. BioTelemetry had a return on equity of 13.66% and a net margin of 16.10%. The business had revenue of $91.70 million during the quarter, compared to the consensus estimate of $88.33 million. During the same period in the prior year, the firm posted $0.23 EPS. The business’s revenue for the quarter was up 69.8% on a year-over-year basis.
Shares of BioTelemetry (NASDAQ:BEAT) traded down $1.25 during trading on Thursday, reaching $33.05. 602,749 shares of the company were exchanged, compared to its average volume of 412,423. The company has a current ratio of 1.60, a quick ratio of 1.48 and a debt-to-equity ratio of 0.75. BioTelemetry has a 12-month low of $23.30 and a 12-month high of $39.20. The stock has a market cap of $1,110.00, a PE ratio of 25.23, a price-to-earnings-growth ratio of 1.47 and a beta of 0.67.
A number of brokerages recently weighed in on BEAT. BidaskClub cut shares of BioTelemetry from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research raised shares of BioTelemetry from a “strong sell” rating to a “hold” rating in a research report on Monday, January 22nd. Raymond James Financial began coverage on shares of BioTelemetry in a research report on Thursday, October 26th. They set an “outperform” rating and a $37.00 price target for the company. Finally, Dougherty & Co reaffirmed a “buy” rating and set a $40.00 price target on shares of BioTelemetry in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $42.86.
TRADEMARK VIOLATION NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/02/22/biotelemetry-beat-posts-earnings-results-beats-expectations-by-0-09-eps.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.